2022-07-11T13:31:44-05:00 2021-12-31 520982413 GROSS MENDELSOHN & ASSOCIATES PA 1801 PORTER STREET SUITE 500 BALTIMORE MD 21230 990 2021-01-01 954132414 CURESEARCH FOR CHILDREN'S CANCER CURE 2402352200 4800 HAMPDEN LANE PMB 183 200 BETHESDA MD 20814 KAY KOEHLER CEO 2402352200 2022-07-11 1 KAY KOEHLER 999009999 JAMES E CRISP P00025401 4106855512 2022-07-05 3 AAL1 IAL1 2021 2022-09-23 18:48:47Z KAY KOEHLER 4800 HAMPDEN LANE PMB 183 200 BETHESDA MD 20814 7651490 0 X WWW.CURESEARCH.ORG X 1987 CA CURESEARCH FUNDS AND SUPPORTS CHIDLREN'S CANCER RESEARCH AND PROVIDES EDUCATION AND RESOURCES TO ALL THOSE AFFECTED BY CHILDREN'S CANCER. 18 18 22 750 0 0 2997810 3394705 0 0 178125 400190 1459342 2450335 4635277 6245230 1628115 2146975 0 0 1854382 1904555 0 0 696103 711432 740907 4193929 4792437 441348 1452793 7250521 8075617 946340 441681 6304181 7633936 X CURESEARCH'S MISSION IS TO FUND AND SUPPORT TARGETED AND INNOVATIVE CANCER RESEARCH WITH MEASURABLE RESULTS, AND TO BE THE AUTHORITATIVE SOURCE OF INFORMATION AND RESOURCES FOR ALL THOSE AFFECTED BY CHILDREN'S CANCER.(SEE SCHEDULE O FOR CONTINUATION)CURESEARCH SUPPORTS CHILDHOOD CANCER RESEARCH AT ALL STAGES ALONG THE RESEARCH CONTINUUM, FROM FELLOWSHIPS THAT ACCELERATE THE CAREERS OF YOUNG RESEARCHERS TO MULTI-MILLION DOLLAR GRANTS THAT SUPPORT RESEARCH TEAMS DEVELOPING POTENTIAL NEW TREATMENTS, TO CLINICAL TRIAL AWARDS THAT ENABLE HOSPITALS TO ENROLL CHILDREN BEING TREATED TODAY. IT PROVIDES EDUCATIONAL RESOURCES TO PARENTS AND CAREGIVERS, INCLUDING PLAIN LANGUAGE INFORMATION ON DIAGNOSIS AND TREATMENT, PROCEDURAL VIDEOS, AND PARENT WEBINARS. CURESEARCH ALSO RAISES FUNDS THROUGH INDIVIDUALS, CORPORATIONS, PRIVATE FOUNDATIONS, AND SPECIAL EVENTS. 0 0 3533912 2146975 CURESEARCH SUPPORTS RESEARCH EFFORTS TO IMPROVE TREATMENTS AND FIND CURES FOR CHILDREN'S CANCER. THROUGH COMPETITIVE GRANT MAKING INITIATIVES, CURESEARCH FUNDS RESEARCH TEAMS ACROSS THE COUNTRY THAT STUDY MORE THAN 13 TYPES OF CANCER IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH THE GOAL OF IMPROVING CURRENT TREATMENTS, DEVELOPING NEW THERAPIES, AND UNDERSTANDING THE BIOLOGY OF MORE PEDIATRIC CANCER DISEASE TYPES. CURESEARCH FUNDS RESEARCH AT ALL STAGES OF THE PIPELINE, INCLUDING BASIC SCIENCE, TRANSLATIONAL RESEARCH, CLINICAL TRIAL DEVELOPMENT, AND THE TESTING OF NEW CANCER THERAPIES. THIS RESEARCH IMPACTS OVER 14,900 CHILDREN DIAGNOSED WITH CANCER EACH YEAR WITH THE LONG-TERM GOAL OF DEVELOPING THERAPIES THAT CURE CHILDREN TODAY WITHOUT HARMING THEM TOMORROW. (SEE SCHEDULE O FOR CONTINUATION)CURESEARCH FUNDS CLINICAL TRIALS ACROSS THE COUNTRY. CLINICAL TRIALS ENSURE THAT CHILDREN WITH CANCER GET ACCESS TO THE BEST CURRENT TREATMENTS. THE DATA COLLECTED FROM CLINICAL TRIALS ENABLES RESEARCHERS TO ACHIEVE A BETTER UNDERSTANDING OF CANCER BIOLOGY AND GUIDES THE DEVELOPMENT OF NEW TREATMENTS AND TREATMENT PROTOCOLS. CLINICAL TRIALS ARE COSTLY FOR HOSPITALS, WHICH RELY ON SUPPORT FROM CURESEARCH AND OTHER ORGANIZATIONS TO BE ABLE TO PROVIDE TREATMENT FOR CHILDREN WITH CANCER. EACH YEAR, ALMOST 10,000 CHILDREN ARE ENROLLED IN CLINICAL TRIALS. IN ADDITION TO FUNDING RESEARCH, CURESEARCH ALSO PROVIDES INFORMATION AND RESOURCES TO PATIENTS AND FAMILIES. CURESEARCH RESOURCES INCLUDE CURESEARCH.ORG, AN ONLINE RESOURCE WITH PLAIN LANGUAGE INFORMATION ON DIAGNOSIS AND TREATMENT FOR CHILDREN'S CANCER; A LIBRARY OF PROCEDURE VIDEOS THAT DEMONSTRATE CANCER TREATMENTS FOR CHILDREN; AND WEBINARS AND GUIDES FOR PARENTS ON COPING WITH CANCER, FINDING COMMUNITY SUPPORT, AND REINTEGRATING A CHILD INTO SCHOOL AND SOCIAL ENVIRONMENTS. THESE RESOURCES AID ABOUT 28,500 INDIVIDUALS EACH YEAR. 3533912 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 16 0 1 22 1 0 0 0 0 0 0 0 0 0 0 X 18 18 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 AL AK AZ AR CA CO CT FL GA IL KS KY ME MD MA MI MN MS NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X X MANAGEMENT 2402352200 4800 HAMPDEN LANE PMB 183 SUITE 200 BETHESDA MD 20814 KAY KOEHLER CEO 40.00 X 356981 0 23490 KATHARINE BURKE COO & VP FINANCE 40.00 X 212218 0 15550 JARED D BRANCAZIO CHAIR 1.00 X X 0 0 0 MICHAEL R MILLER ESQUIRE SECRETARY 1.00 X X 0 0 0 TIFFANI COPELAND SVP DEVELOPMENT & COMMUNIC 40.00 X 183331 0 8769 TRENT DEMULLING TREASURER 1.00 X X 0 0 0 HANK ADAMS DIRECTOR 1.00 X 0 0 0 SAMUEL BLACKMAN MD PHD DIRECTOR 1.00 X 0 0 0 CASON CARTER DIRECTOR 1.00 X 0 0 0 PAULA CARTER DIRECTOR 1.00 X 0 0 0 SHARI COLLIER DIRECTOR 1.00 X 0 0 0 SUZANNE FINNEGAN DIRECTOR 1.00 X 0 0 0 ANNIE GOULD DIRECTOR 1.00 X 0 0 0 DAVID KUPIEC DIRECTOR 1.00 X 0 0 0 STUART E SIEGEL MD DIRECTOR 1.00 X 0 0 0 JEFFREY SKOLNIK DIRECTOR 1.00 X 0 0 0 TINA SWALLOW DIRECTOR 1.00 X 0 0 0 KATHY WANNER DIRECTOR 1.00 X 0 0 0 MA CHERRY TRIVEDI DIRECTOR 1.00 X 0 0 0 BRENDA WEIGEL DIRECTOR 1.00 X 0 0 0 DAVID WHAN DIRECTOR 1.00 X 0 0 0 RICHARD PAYNE EMERITUS DIRECTOR 1.00 X 0 0 0 MARY PAYNE EMERITUS DIRECTOR 1.00 X 0 0 0 752530 0 47809 3 0 1 0 0 555600 2839105 16152 3394705 88403 88403 1519737 1207950 311787 311787 311787 2607244 198310 2408934 2408934 MISCELLANEOUS REVENUE 541700 41401 41401 41401 6245230 0 0 2850525 2146975 2146975 608239 418261 151931 38047 1085401 581071 124557 379773 17805 9611 1781 6413 80231 44411 10162 25658 112879 66363 18172 28344 50650 50650 54699 54699 22391 22391 67755 49106 7285 11364 36062 21202 5805 9055 137270 80703 22098 34469 13799 8113 2221 3465 46182 1197 2953 42032 38600 36500 2100 50063 29433 8059 12571 BANK FEES 85960 6862 79098 PUBLIC RELATIONS 71869 41678 17492 12699 DUES AND SUBSCRIPTIONS 37753 22195 6078 9480 OTHER PERSONNEL EXPENSE 16113 13593 985 1535 11741 11741 4792437 3533912 562422 696103 769157 1696856 388881 425628 1718042 832045 83995 56921 0 0 0 0 4266397 5050992 24049 13175 7250521 8075617 173448 209900 495092 231781 277800 0 946340 441681 X 1233605 2887229 5070576 4746707 6304181 7633936 7250521 8075617 1452793 -123038 0 X X 0 1 X 1 0 X 1796520 1870428 2749767 2997810 3394705 12809230 1796520 1870428 2749767 2997810 3394705 12809230 3520155 9289075 133702 107185 117039 92534 88403 538863 36875 791 6107 11262 41401 96436 13444529 11255801 0.69090 0.64150 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS - 2017 AMOUNT: $ 36,875. 2018 AMOUNT: $ 791. 2019 AMOUNT: $ 6,107. 2020 AMOUNT: $ 11,262. 2021 AMOUNT: $ 41,401. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 2448109 298261 100000 2464370 2206331 341778 100000 2448109 1938383 367948 100000 2206331 2152233 -113850 100000 1938383 2969834 277370 1094971 2152233 0.56680 0.43320 0 0 0 X 6144555 -123038 44754 -78284 6222839 22391 22391 6245230 4814800 44754 44754 4770046 22391 22391 4792437 PART V, LINE 4: DONOR RESTRICTED ENDOWMENT FUND HAS BEEN ESTABLISHED TO ADVANCE PEDIATRIC CANCER RESEARCH BY DISEASE, BY MEDICAL DISCIPLINE, OR THROUGH RESEARCH FELLOWSHIPS. PART X, LINE 2: IN ACCORDANCE WITH FIN 48 (ASC 740), INCOME TAXES, MANAGEMENT EVALUATED ITS ACTIVITIES AND DETERMINED THAT CURESEARCH HAD TAKEN NO UNCERTAIN TAX POSITIONS THAT REQUIRE ADJUSTMENT TO OR DISCLOSURE IN THE FINANCIAL STATEMENTS TO COMPLY WITH THE PROVISIONS OF THE ACCOUNTING STANDARD. IN GENERAL, THE ORGANIZATION'S FEDERAL EXEMPT ORGANIZATION TAX RETURNS ARE SUBJECT TO EXAMINATION BY THE IRS, GENERALLY FOR A PERIOD OF THREE YEARS AFTER THE RETURNS ARE FILED. PART XI, LINE 2D - OTHER ADJUSTMENTS: INDIRECT COST OF BENEFITS OF SPECIAL EVENTS 44,754. PART XII, LINE 2D - OTHER ADJUSTMENTS: INDIRECT COST OF SPECIAL EVENTS 44,754. WALK/RUN EVENT 2607244 2607244 15282 111051 10454 61523 2607244 2607244 15282 111051 10454 61523 198310 2408934 1 DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVE BP412 BOSTON MA 022155450 422263040 501 (C) (3) 75000 0 THERAPEUTIC STANFORD UNIVERSITY 3712 PORTER DRIVE PALO ALTO CA 94304 941156365 501 (C) (3) 400000 0 THERAPEUTIC UNIVERSITY OF FLORIDA PO BOX 113201 GAINESVILLE FL 326113201 596002052 501 (C) (3) 1375000 0 THERAPEUTIC UNIVERSITY COLORADO 1800 GRANT STREET SUITE 400 DENVER CO 80203 846000555 501 (C) (3) 46975 0 THERAPEUTIC YALE UNIVERSITY PO BOX 1873 NEW HAVEN CT 065081873 060646973 501 (C) (3) 75000 0 THERAPEUTIC JOHNS HOPKINS 3910 KESWICK ROAD N4327B BALTIMORE MD 21211 520595110 501 (C) (3) 75000 0 THERAPEUTIC AUGUSTA UNIVERSITY MEDICAL COLLEGE OF GEORGIA 1120 15TH STREET AUGUSTA GA 30912 586002053 501 (C) (3) 100000 0 THERAPEUTIC 7 PART I, LINE 2: CURESEARCH'S MANAGEMENT WILL REQUEST PERIODIC REPORTS AND STATUS UPDATES OF ITS GRANT AWARDS THROUGHOUT THE YEAR. X X X X 0 0 0 0 0 0 0 0 0 KAY KOEHLER CEO 356981 0 0 0 0 0 5800 0 17690 0 380471 0 0 0 KATHARINE BURKE COO & VP FINANCE 212218 0 0 0 0 0 4244 0 11306 0 227768 0 0 0 TIFFANI COPELAND SVP DEVELOPMENT & COMMUNIC 183331 0 0 0 0 0 3667 0 5102 0 192100 0 0 0 FORM 990, PART VI, SECTION A, LINE 2 THE MEMBERSHIP OF CURESEARCH'S BOARD OF DIRECTORS INCLUDES PAULA AND CASON CARTER (MOTHER AND SON). IT ALSO INCLUDES RICHARD PAYNE AND MARY PAYNE (HUSBAND AND WIFE), WHO ARE EMERITUS DIRECTORS. FORM 990, PART VI, SECTION B, LINE 11B THE ORGANIZATION RETAINS AN OUTSIDE CPA TO PREPARE THE IRS FORM 990. PRIOR TO FILING, THE COMPLETED RETURN IS REVIEWED IN DETAIL BY THE CEO/PRESIDENT AND PRESENTED TO THE EXECUTIVE COMMITTEE OF THE BOARD. FORM 990, PART VI, SECTION B, LINE 12C EACH YEAR, ALL DIRECTORS, OFFICERS AND KEY EMPLOYEES ARE PROVIDED WITH THE CONFLICT OF INTEREST POLICY FOR REVIEW. ALL NEW EMPLOYEES ARE REQUIRED TO READ THE CONFLICT OF INTEREST POLICY AND SIGN IT AS PART OF THEIR ORIENTATION. ALL EMPLOYEES ARE REQUIRED TO READ AND RE-SIGN THE CONFLICT INTEREST POLICY ON AN ANNUAL BASIS. THE POLICY REQUIRES THAT ANYONE WHO KNOWS OF AN ACTUAL OR PERCEIVED CONFLICT OF INTEREST MUST REPORT IT. FORM 990, PART VI, SECTION B, LINE 15A COMPENSATION OF THE CEO WAS DETERMINED BY THE BOARD OF DIRECTORS USING AVAILABLE PUBLIC INFORMATION FOR COMPENSATION LEVELS AND AN EVALUATION OF THE ORGANIZATION'S PERFORMANCE AS WELL AS THAT OF THE CEO. THIS PROCESS IS DOCUMENTED IN THE BOARD MINUTES. FORM 990, PART VI, SECTION C, LINE 19 CURESEARCH'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. CURESEARCH'S FINANCIAL STATEMENTS AND FORM 990S ARE AVAILABLE ON ITS WEBSITE - CURESEARCH.ORG 990 PART VII, LINE 2C PROCESS HAS NOT CHANGED FROM PRIOR YEAR